ScPharmaceuticals Hopes To Win Payer Favor As It Prepares For Furoscix Resubmission

 
• By Alaric DeArment
  
heart failure illustration
scPharmaceuticals announced data from its FREEDOM-HF study of Furoscix, which it plans to resubmit to the FDA in Q4 • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business